Rescue medication use as a patient-reported outcome in COPD: A systematic review and regression analysis

Respiratory Research

Volumn 18, Issue 1, 2017, Pages

  Punekar, Yogesh Suresh ^a   Sharma, Sheetal ^b   Pahwa, Ankit ^b   Takyar, Jitender ^b   Naya, Ian ^c   Jones, Paul W ^d  

^a VIIV HEALTHCARE   (United States)

^b PAREXEL INTERNATIONAL   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

COPD; Inhaled corticosteroid; Long acting muscarinic antagonist; Long acting 2 agonist; Lung function outcomes; Patient reported outcomes; Rescue medication use

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG USE; FORCED EXPIRATORY VOLUME; HUMAN; OUTCOME ASSESSMENT; PATIENT-REPORTED OUTCOME; RESCUE MEDICATION USE; RESPIRATORY TRACT DISEASE ASSESSMENT; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYSTEMATIC REVIEW; TRANSITION DYSPNEA INDEX; TREATMENT DURATION; ADULT; FEMALE; INHALATIONAL DRUG ADMINISTRATION; MALE; META ANALYSIS; MIDDLE AGED; PREVALENCE; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; REPRODUCIBILITY; RISK FACTOR; SELF REPORT; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; UTILIZATION REVIEW;

ADMINISTRATION, INHALATION; ADULT; BIOMARKERS; BRONCHODILATOR AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT REPORTED OUTCOME MEASURES; PREVALENCE; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SELF REPORT; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; UTILIZATION REVIEW;

EID: 85019146089     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-017-0566-1     Document Type: Article

References (17)

1. Celli BR, Macnee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932-46.
2. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, updated 2016. http://www.goldcopd.com/. Accessed 6 June 2016.
3. Jenkins CR, Postma DS, Anzueto AR, Make BJ, Peterson S, Eriksson G, et al. Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease. BMC Pulm Med. 2015;15:97-105.
4. Jones PW, Anderson JA, Calverley PM, Celli BR, Ferguson GT, Jenkins C, et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respir Res. 2011;12:71-8.
5. 1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res. 2011;12:40-8.
6. 1 and patient-reported outcomes changes: results of a meta-analysis of randomized trials in stable COPD. COPD: Chronic Obstr Pulm Dis. 2016;3:519-38.
7. Global Strategy for Asthma Management and Prevention, updated 2016. http://ginasthma.org/. Accessed 6 June 2016.
8. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
9. Jones PW, Donohue JF, Nedelman J, Pascoe S, Pinault G, Lassen C. Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis. Respir Res. 2011;12:161-70.
10. Decramer ML, Chapman KR, Dahl R, Frith P, Devouassoux G, Fritscher C, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med. 2013;1:524-33.
11. Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005;2:111-24.
12. Jones PW. St. George's Respiratory Questionnaire: MCID. COPD. 2005;2:75-9.
13. Mahler DA, Witek Jr TJ. The MCID of the transition dyspnea index is a total score of one unit. COPD. 2005;2:99-103.
14. Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013;1:210-23.
15. Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016;374:2222-34.
16. Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandstrom T, Taylor AF, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1:199-209.
17. Leidy NK, Sexton CC, Jones PW, Notte SM, Monz BU, Nelsen L, et al. Measuring respiratory symptoms in clinical trials of COPD: reliability and validity of a daily diary. Thorax. 2014;69:443-9.